Drug
Azd1722
Azd1722: highest development phase Phase 2, developed by Ardelyx. 7 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Ardelyx
Trials
| Drug | Phase | Indication |
|---|---|---|
| AZD1722 NCT02081534 | Phase 2 | Hyperphosphatemia |
| AZD1722 (in-patient) NCT01764854 | Phase 2 | End Stage Renal Disease |
| AZD1722 NCT01847092 | Phase 2 | Chronic Kidney Disease |
| AZD1722 NCT02176252 | Phase 1 | Healthy Volunteer |
| AZD1722 NCT02249936 | Phase 1 | Healthy |
| AZD1722 NCT02063386 | Phase 1 | Healthy Volunteers |
| AZD1722 NCT02346890 | Phase 1 | Healthy |
Latest
No recent events.
Follow Azd1722 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.